Rick joined the Aviva Investors Global Responsible Investment team in 2018 with a primary focus on climate change and responsibility for ESG coverage of the industrials sector.
Experience and qualifications
Rick has almost 20 years’ experience in responsible investment. He was Head of Responsible Investment at Schroders for 16 years and a Global Director at the CDP (formerly known as the Carbon Disclosure Project) for two years. He has a Bachelors in Agriculture and Food Science and a Masters in Environmental Technology. Rick has a particular interest in syntropic agriculture and the dual role of forests in building resilience in the food system and combating climate change.
Associate Director Responsible Investment
Impact Analyst - Social Pillar Lead
Senior Corporate Governance Analyst
Senior Manager, Sustainable Finance Centre for Excellence
Senior ESG Analyst
Chief Responsible Investment Officer
Senior Corporate Governance Analyst
Senior ESG analyst
Senior ESG Analyst & Earth Pillar Lead
ESG Operations Manager
Global Head of ESG and Strategic Partnerships
Global Head of ESG Investments
ESG Associate Director, Real Assets
Head of ESG – Sovereign
You might also be interested in
Global equity income Q&A: Richard Saldanha on the outlook for dividends and growth
3 Aug. 2022
The lead manager of our Global Equity Income strategy discusses risks and opportunities for income-seeking investors in a turbulent time for markets.
The AIQ Podcast: Taking stock of nature risk
15 Jul. 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
Investing in a just transition to net zero: A Q&A with Nick Robins
30 Jun. 2022
Reaching net zero by 2050 will require significant injections of capital. But it is also an opportunity to rethink social relationships, as Professor Nick Robins explains.
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun. 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
What does the data say? Biodiversity loss: From horror to hope
24 Jun. 2022
In this month’s instalment of our visual series on topical themes, we explore the world of biodiversity.
ESG investing: Lasting lessons from Russia’s war on Ukraine
23 Jun. 2022
Russia’s invasion of Ukraine has led to ESG receiving widespread flak. While much of the criticism is unjustified, the episode underlines how many issues related to ESG are complex and involve trade-offs. Investment approaches may need fine tuning, especially if the geopolitical landscape continues to change so rapidly.
Antimicrobial resistance: Q&A with Dame Sally Davies
10 Jun. 2022
Resistance to antibiotics is already killing millions. Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance, spoke to AIQ on the latest developments to counter antimicrobial resistance Antimicrobial Resistance (AMR) in the UK and globally.
The AIQ Podcast: Investing towards a new social contract
9 Jun. 2022
As life returns to some form of normality, governments are free to move their focus from COVID-19 to left-behind communities and delivering a just transition. This is important to secure long-term economic outcomes, but also comes with investment opportunities and risks.
Deep water: Ten threats to marine ecosystems
8 Jun. 2022
Our air, weather, food, the health of diverse marine life and millions of jobs all depend on the ocean. But we have not done well as custodians of marine ecosystems. Here, we set out ten ways where human actions threaten the health of an essential environment.
The investment case for nature
17 May 2022
The impact of economic activity on the natural world has long been ignored. However, governments, companies and investors can all play a role in helping to protect nature.
Levelling up: Investing towards a new social contract
17 May 2022
As we learn to live with COVID-19, focus is returning to delivering a just transition. This is important to secure long-term investment outcomes, but also presents direct opportunities.
Life force: Why nature matters
12 May 2022
Growing awareness that natural systems are stressed or even close to breakdown is prompting asset managers to look closely at nature-based risks and investee companies to understand their environmental impacts and dependencies.
Why investors must act now on the biodiversity crisis
26 Apr. 2022
The concepts of biodiversity and ‘natural capital’ have been largely ignored by business and finance until recently. Investors are now starting to take the issue seriously and build it into their thinking.
Facing up to the ESG backlash
6 Apr. 2022
Asset managers must better explain how ESG can improve investment returns and make the world a better place. Clear guidance to help investors choose between funds is also required.
Back to nature: Why we must act now on the biodiversity crisis
31 Mar. 2022
In an age of mass extinctions, policymakers, businesses and financial institutions are beginning to acknowledge the risks associated with biodiversity loss, along with the opportunities that arise from nature-positive solutions.
Power to the people: The moral and investment case for human rights
30 Mar. 2022
Healthy and happy employees, consumers, and communities are all critical ingredients in a company’s long-term success. Investors have a key responsibility in ensuring the rights of these groups are respected.